PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer

Sponsor
The First Affiliated Hospital of Zhengzhou University
Study ID
NCT07294664
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Advanced Gastric Cancer
  • SHR1701

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SHR1701 — DRUG
    SHR1701:1800mg,d1,Q3W
  • SHR2554 — DRUG
    SHR2554 350mg,bid
  • CAPOX — DRUG
    Capecitabine:1000mg/kg,bid,d1-d14,Q3W Oxaliplatin:130mg/m2,d1,Q3W
  • Apatinib — DRUG
    250 mg, qd

Study Details

Immunotherapy combined with chemotherapy has become the standard first-line treatment regimen for gastric cancer. However, a subset of patients still fail to benefit or derive only limited benefit from this approach. This study aims to evaluate the addition of immunomodulatory EZH2 inhibitors or anti-angiogenic agents to the baseline regimen of immunotherapy combined with chemotherapy, in order to further improve patient treatment benefits.

Key Dates

Start date
Jun 15, 2025
Status verified
Dec 2025
Primary completion
Jul 15, 2027
Completion
Jul 15, 2028

Study Design

Enrollment
78 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: SHR1701+SHR2554+CAPOX
  • Experimental: SHR1701+Apatinib+CAPOX

Primary Outcome Measure

ORR [ Time Frame: assessed up to 1 year ]

Central Contacts

Related Studies